Study on the Efficacy and Safety of Ultrasound-Guided Peritendinous Injection of Low-Molecular-Weight Hyaluronic Acid (Hyalotend®; 500-730 kDa) for Chronic Non-Calcific Supraspinatus Tendinopathy.

Prospective Single-Arm Observational Study on the Efficacy and Safety of Ultrasound-Guided Peritendinous Injection of Low-Molecular-Weight Hyaluronic Acid (Hyalotend®; 500-730 kDa) for Chronic Non-Calcific Supraspinatus Tendinopathy.

This study aims to evaluate whether ultrasound-guided injections of low-molecular-weight hyaluronic acid (Hyalotend®) can safely reduce pain and improve shoulder function in people with chronic non-calcific supraspinatus tendinopathy. Participants will receive two injections as part of their treatment and will be followed over time to assess changes in pain, shoulder function, medication use, treatment satisfaction, and any side effects. The information collected may help improve the treatment of this condition in future patients.

Inclusion Criteria:

• Age ≥18 years.
• Clinical and ultrasound-confirmed diagnosis of chronic (>12 weeks) supraspinatus tendinopathy.
• No structural tendon tear, confirmed by ultrasound.
• No tendon calcification, confirmed by ultrasound.
• Previous failure of conservative treatment, including physical therapy and/or analgesic or anti-inflammatory medication.
• Written informed consent provided.

Exclusion Criteria:

• Partial- or full-thickness supraspinatus tendon tear identified by ultrasound.
• Calcific supraspinatus tendinopathy identified by ultrasound.
• Subacromial-subdeltoid bursitis identified by ultrasound
• Previous treatment with extracorporeal focus shock wave therapy within the last 3 months.
• Previous corticosteroid or platelet-rich plasma (PRP) injection within the last 3 months.
• History of hypersensitivity or allergy to hyaluronic acid or any of its components.
• Uncontrolled systemic disease.
• Other chronic rheumatologic or autoimmune diseases.
• Pregnancy or breastfeeding.